Paul S. Aisen
Clinical trials sponsored by Paul S. Aisen, explained in plain language.
-
Major trial takes on Alzheimer's tau tangles with multiple drugs
Disease control Not yet recruitingThis study tests whether drugs that target tau protein, alone or with another drug (donanemab), can slow Alzheimer's in people aged 50–80 with very early symptoms. About 900 participants will receive different treatments or placebos over 30 months, with regular brain scans and me…
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could a tau vaccine slow Alzheimer's? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether AADvac1, a vaccine-like therapy targeting tau protein, alone or with donanemab, can reduce tau buildup in the brain and slow Alzheimer's progression. About 450 adults aged 50-80 with early Alzheimer's will participate. The goal is to see if this a…
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated May 11, 2026 20:40 UTC